Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Babar Bashir

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|August 19, 2015
Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung PrimaryJennifer Shih, Babar Bashir, Karen S Gustafson, et al.
JMIR Formative Research|November 10, 2023
Feasibility of a Text Messaging-Integrated and Chatbot-Interfaced Self-Management Program for Symptom Control in Patients With Gastrointestinal Cancer Undergoing Chemotherapy: Pilot Mixed Methods StudySameh Gomaa, James Posey, Babar Bashir, et al.
Therapeutic Advances in Urology|June 26, 2023
Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancerKevin K Zarrabi, Vivek Narayan, Patrick J Mille, et al.
Urologic Oncology|June 21, 2021
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?Jean Hoffman-Censits, Kara Lombardo, David McConkey, et al.
Expert Review of Precision Medicine and Drug Development|May 24, 2021
GUCY2C as a biomarker to target precision therapies for patients with colorectal cancerAmanda N Lisby, John C Flickinger, Babar Bashir, et al.
Cancer Biology & Therapy|February 11, 2020
APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axisErik S Blomain, Jeffrey A Rappaport, Amanda M Pattison, et al.
Investigational New Drugs|February 19, 2024
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinomaKathryn E Beckermann, Amita Patnaik, Ira Winer, et al.
Clinical Journal of Gastroenterology|April 8, 2023
Salvage endoscopic ultrasound-guided gastrojejunostomy as a bridge to definitive surgical therapy for duodenal adenocarcinoma presenting with duodenal stent obstructionTiffany Z Yu, Abishek Agnihotri, Richard Zheng, et al.
Human Pathology|February 5, 2019
Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasiaBabar Bashir, Dante J Merlino, Jeffrey A Rappaport, et al.
Clinical and Translational Science|April 19, 2022
Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipientsHolly Mansell, Ahmed Shoker, Jane Alcorn, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Journal of the National Comprehensive Cancer Network : JNCCN|August 19, 2015
Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung PrimaryJennifer Shih, Babar Bashir, Karen S Gustafson, et al.
JMIR Formative Research|November 10, 2023
Feasibility of a Text Messaging-Integrated and Chatbot-Interfaced Self-Management Program for Symptom Control in Patients With Gastrointestinal Cancer Undergoing Chemotherapy: Pilot Mixed Methods StudySameh Gomaa, James Posey, Babar Bashir, et al.
Therapeutic Advances in Urology|June 26, 2023
Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancerKevin K Zarrabi, Vivek Narayan, Patrick J Mille, et al.
Urologic Oncology|June 21, 2021
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?Jean Hoffman-Censits, Kara Lombardo, David McConkey, et al.
Expert Review of Precision Medicine and Drug Development|May 24, 2021
GUCY2C as a biomarker to target precision therapies for patients with colorectal cancerAmanda N Lisby, John C Flickinger, Babar Bashir, et al.
Cancer Biology & Therapy|February 11, 2020
APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axisErik S Blomain, Jeffrey A Rappaport, Amanda M Pattison, et al.
Investigational New Drugs|February 19, 2024
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinomaKathryn E Beckermann, Amita Patnaik, Ira Winer, et al.
Clinical Journal of Gastroenterology|April 8, 2023
Salvage endoscopic ultrasound-guided gastrojejunostomy as a bridge to definitive surgical therapy for duodenal adenocarcinoma presenting with duodenal stent obstructionTiffany Z Yu, Abishek Agnihotri, Richard Zheng, et al.
Human Pathology|February 5, 2019
Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasiaBabar Bashir, Dante J Merlino, Jeffrey A Rappaport, et al.
Clinical and Translational Science|April 19, 2022
Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipientsHolly Mansell, Ahmed Shoker, Jane Alcorn, et al.
Pageof 5